Takeda Pharmaceutical Company Limited (BVMF:TAKP34)
Brazil flag Brazil · Delayed Price · Currency is BRL
73.22
+1.89 (2.65%)
At close: Nov 7, 2025

BVMF:TAKP34 Ratios and Metrics

Millions BRL. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Nov '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2016 - 2020
236,757258,429217,670257,575212,264318,402
Upgrade
Market Cap Growth
-7.00%18.73%-15.49%21.35%-33.34%28.41%
Upgrade
Enterprise Value
391,111447,498380,767413,967354,375555,175
Upgrade
Last Close Price
73.2285.6865.8177.22--
Upgrade
PE Ratio
198.7762.5445.5721.3323.5716.57
Upgrade
PS Ratio
1.491.471.541.681.521.95
Upgrade
PB Ratio
0.920.970.901.060.951.20
Upgrade
P/FCF Ratio
6.467.8812.148.085.426.92
Upgrade
P/OCF Ratio
5.486.399.166.924.836.16
Upgrade
EV/Sales Ratio
2.592.552.692.702.543.40
Upgrade
EV/EBITDA Ratio
9.669.4810.048.467.6511.04
Upgrade
EV/EBIT Ratio
23.7720.7622.9917.5415.0925.62
Upgrade
EV/FCF Ratio
10.6713.6521.2312.999.0612.07
Upgrade
Debt / Equity Ratio
0.730.730.750.770.850.98
Upgrade
Debt / EBITDA Ratio
4.373.964.573.794.075.16
Upgrade
Debt / FCF Ratio
5.105.9410.105.814.815.64
Upgrade
Asset Turnover
0.300.310.290.300.270.25
Upgrade
Inventory Turnover
1.241.301.301.361.401.34
Upgrade
Quick Ratio
0.650.440.500.490.731.00
Upgrade
Current Ratio
1.371.011.110.971.211.53
Upgrade
Return on Equity (ROE)
0.47%1.52%2.12%5.27%4.24%7.60%
Upgrade
Return on Assets (ROA)
2.09%2.40%2.15%2.85%2.88%2.06%
Upgrade
Return on Capital (ROIC)
2.44%2.84%2.61%3.57%3.62%2.59%
Upgrade
Return on Capital Employed (ROCE)
3.90%4.80%3.90%5.40%5.40%3.80%
Upgrade
Earnings Yield
0.50%1.60%2.20%4.69%4.24%6.04%
Upgrade
FCF Yield
15.48%12.69%8.24%12.37%18.44%14.44%
Upgrade
Dividend Yield
4.04%8.76%9.47%8.88%--
Upgrade
Payout Ratio
935.06%280.28%199.34%88.14%123.30%75.36%
Upgrade
Buyback Yield / Dilution
-0.65%-1.58%-0.67%0.46%-0.23%-0.47%
Upgrade
Total Shareholder Return
3.39%7.18%8.81%9.34%-0.23%-0.47%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.